Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Koehler

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Scientific Reports|May 4, 2017
Enzyme discovery beyond homology: a unique hydroxynitrile lyase in the Bet v1 superfamilyElisa Lanfranchi, Tea Pavkov-Keller, Eva-Maria Koehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptorMaurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2024
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with RadiotherapyVictor Ng, Sonali Sinha, Ardijana Novaj, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Journal of the National Cancer Institute|January 25, 2022
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic ImplicationsTony El Jabbour, Maksym Misyura, Darren Cowzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny, Boris Winterhoff, Teodora Kolarova, et al.
Journal for Immunotherapy of Cancer|May 11, 2025
The cold immunological landscape of ATM-deficient cancersSonali Sinha, Victor Ng, Ardijana Novaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Scientific Reports|May 4, 2017
Enzyme discovery beyond homology: a unique hydroxynitrile lyase in the Bet v1 superfamilyElisa Lanfranchi, Tea Pavkov-Keller, Eva-Maria Koehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptorMaurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
The Lancet. Oncology|March 8, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialMassimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2024
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with RadiotherapyVictor Ng, Sonali Sinha, Ardijana Novaj, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Journal of the National Cancer Institute|January 25, 2022
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic ImplicationsTony El Jabbour, Maksym Misyura, Darren Cowzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny, Boris Winterhoff, Teodora Kolarova, et al.
Journal for Immunotherapy of Cancer|May 11, 2025
The cold immunological landscape of ATM-deficient cancersSonali Sinha, Victor Ng, Ardijana Novaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B TrialSibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Pageof 4